The characterization and classification of concurrent blood group antibodies

Transfusion

Volumn 49, Issue 12, 2009, Pages 2709-2718

  Stack, Gary ^a,b   Tormey, Christopher A ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BLOOD GROUP ANTIBODY;

ALLOIMMUNIZATION; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ARTICLE; BLOOD TRANSFUSION; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; MALE;

BLOOD GROUP ANTIGENS; BLOOD GROUP INCOMPATIBILITY; BLOOD TRANSFUSION; CONNECTICUT; EPITOPES; FEMALE; HOSPITALS, VETERANS; HUMANS; ISOANTIBODIES; MALE; MODELS, IMMUNOLOGICAL; RETROSPECTIVE STUDIES; SEROEPIDEMIOLOGIC STUDIES;

EID: 71849093813     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02337.x     Document Type: Article

References (28)

1. Rosse WF, Gallagher D, Kinney TR, Castro O, Dosik H, Moohr J, Wang W, Levy PS. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell disease. Blood 1990 76 : 1431 7.
2. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002 42 : 37 43.
3. Castro O, Sandler SG, Houston-Yu P, Rana S. Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion 2002 42 : 684 90.
4. Osby M, Shulman IA. Phenotype matching of donor red blood cell units for nonalloimmunized sickle cell disease patients: a survey of 1182 North American laboratories. Arch Pathol Lab Med 2005 129 : 190 3.
5. Schonewille H, van de Watering LM, Brand A. Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: is it time to take precautionary measures? Transfusion 2006 46 : 630 5.
6. Winters JL, Pineda AA, Gorden LD, Bryant SC, Melton LJ 3rd., Vamvakas EC, Moore SB. RBC alloantibody specificity and antigen potency in Olmsted County, Minnesota. Transfusion 2001 41 : 1413 20.
7. Roback JD. Technical manual. 16th ed. Bethesda (MD) : American Association of Blood Banks 2008.
8. 1R1 patients with anti-E. Immunohematology 2005 21 : 94 6.
9. Shirey RS, Edwards RE, Ness PM. The risk of alloimmunization to c (Rh4) in R1R1 patients who present with anti-E. Transfusion 1994 34 : 756 8.
10. Schonewille H, Brand A. Does an alloimmune response to strong immunogenic red blood cell antigens enhance a response to weaker antigens? Transfusion 2008 48 : 958 63.
11. Tormey CA, Fisk J, Stack G. Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion 2008 48 : 2069 76.
12. Preacher KJ. An interactive calculation tool for chi-square tests of goodness of fit and independence. Lawrence (KS) : The University of Kansas 2008 cited 2009 Jan 5]. Available from: http://www.quantpsy.org
13. Lowry R. VassarStats website for statistical computation. New York : Vassar College 2008 cited 2009 Jan 5]. Available from: http://faculty.vassar. edu/lowry/VassarStats.html
14. Daniels G. Human blood groups. 2nd ed. Oxford : Blackwell Science 2002.
15. Reid ME, Lomas-Francis C. The blood group antigen facts book. 2nd ed. New York : Elsevier 2004.
16. Moore AC, Hutchings CL. Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity. Expert Rev Vaccines 2007 6 : 111 21.
17. Moschos SA, Bramwell VW, Somavarapu S, Alpar HO. Adjuvant synergy: the effects of nasal coadministration of adjuvants. Immunol Cell Biol 2004 82 : 628 37.
18. van den Dobbelsteen GP, van Dijken HH, Pillai S, van Alphen L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine 2007 25 : 2491 6.
19. Dietrich J, Billeskov R, Doherty TM, Andersen P. Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection. J Immunol 2007 178 : 3721 30.
20. Reverberi R. The persistence of red cell alloantibodies. Blood Transfus 2008 6 : 225 34.
21. Ramsey G, Larson P. Loss of red cell alloantibodies over time. Transfusion 1988 28 : 162 5.
22. Tormey CA, Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion 2009 49 : 505 12.
23. Hoeltge GA, Domen RE, Rybicki LA, Schaffer PA. Multiple red cell transfusions and alloimmunization. Experience with 6996 antibodies detected in a total of 159,262 patients from 1985 to 1993. Arch Pathol Lab Med 1995 119 : 42 5.
24. Fluit CR, Kunst VA, Drenthe-Schonk AM. Incidence of red cell antibodies after multiple blood transfusion. Transfusion 1990 30 : 532 5.
25. Redman M, Regan F, Contreras M. A prospective study of the incidence of red cell allo-immunisation following transfusion. Vox Sang 1996 71 : 216 20.
26. Schierman LW, McBride RA. Adjuvant activity of erythrocyte isoantigens. Science 1967 156 : 658 9.
27. Mollison PL, Engelfriet CP, Contreras M. Blood transfusion in clinical medicine. 10th ed. Oxford : Blackwell Science 1997. p. 91 3.
28. Schijns VE. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 2000 12 : 456 63.